In a phase 2a challenge trial of 29 healthy adults inoculated with dengue virus serotype 3, high-dose oral mosnodenvir gave a significantly lower viral RNA load than placebo (P<0.001); 60% vs 0% showed no signs of infection, with no serious adverse events.
RCTn = 29
Durbin et al. Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model